Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. | |
Qin, Shukui; Li, Jin*; Wang, Liwei; Xu, Jianming; Cheng, Ying; Bai, Yuxian; Li, Wei; Xu, Nong; Lin, Li-zhu; Wu, Qiong | |
刊名 | Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
2018 | |
卷号 | 36期号:30页码:JCO2018783183 |
ISSN号 | 0732-183X |
DOI | 10.1200/JCO.2018.78.3183 |
URL标识 | 查看原文 |
WOS记录号 | WOS:000447725000009;PMID:30199311 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3344239 |
专题 | 中南大学 |
作者单位 | [Qin, Shukui] Nanjing Univ Chinese Med, Bayi Hosp, Nanjing, Jiangsu, Peoples R China. |
推荐引用方式 GB/T 7714 | Qin, Shukui,Li, Jin*,Wang, Liwei,et al. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2018,36(30):JCO2018783183. |
APA | Qin, Shukui.,Li, Jin*.,Wang, Liwei.,Xu, Jianming.,Cheng, Ying.,...&Liu, Tianshu.(2018).Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial..Journal of clinical oncology : official journal of the American Society of Clinical Oncology,36(30),JCO2018783183. |
MLA | Qin, Shukui,et al."Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.".Journal of clinical oncology : official journal of the American Society of Clinical Oncology 36.30(2018):JCO2018783183. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论